[1] American Cancer Society (2014) Cancer Facts & Figures 2014. American Cancer Society, Atlanta.
http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index
[2] Stewart, B.W. and Wild, C.P. (2014) World Cancer Report 2014. International Agency for Research on Cancer, France.
http://www.esmo.org/Oncology-News/World-Cancer-Report-2014
[3] O’Callaghan, T. (2011) Introduction: The Prevention Agenda. Nature, 471, S2-S4.
http://www.nature.com/nature/journal/v471/n7339_supp/fig_tab/471S2a_F1.html
http://dx.doi.org/10.1038/471S2a
[4] Tan, Z. (2008) Chinese Patent No. 2007100297361.
[5] Tan, Z., Luo, L., Zhu, E., Yan, R. and Lin, Z. (2010) (3aRS,4SR,7RS,7aSR)-2-(Tricyclo-[3.3.1.1]decan-1-yl)-4,5,6,7- tet-ra-hydro-4,7-epoxyisoindoline-1,3-dione. Acta Crystallographica Section E, 66, Article ID: o1374.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2979399/
http://dx.doi.org/10.1107/S1600536810016971
[6] Tan, Z.Y., Luo, L., Zhu, E.J., Lin, Z.H., Yan, R.S., Zhang, H. and Liang, K. (2010) Preparation and X-Ray Diffraction Analysis of a New Crystal Form of (3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-epoxyisoin-doline-1,3-dione—A Novel Anticancer Compound. Journal of Guangdong Pharmaceutical College, 26, 441-444.
http://www.cqvip.com/QK/90465A/201006/37126978.html
[7] Tan, Z.Y., Yan, R.S., Lu, J.H., Ye, Q., Guan, W.S., Zhang, X.L. and Yang, H. (2012) Determination of (3aRS,4SR, 7RS,7aSR)-2-(Tricyclo-[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-epoxyisoindoline-1,3-dione (SU2162) in Rat Plasma by High-Performance Liquid Chromatography with UV Detection. The Analytical Chemistry, 11, 347-352.
[8] Tan, Z., Yang, H., Yan, R., Liu, R., Li, X., Ye, Q., Guan, W., Zhang, X., Huang, Y., Tong, C. and Chen, W. (2014) Pharmacokinetics and Tissue Distribution of SU2162, a Novel Anticancer Drug, after Intravenous Administration in Rats. Journal of Pharmaceutical Technology and Drug Research, 3, 1-6.
http://www.hoajonline.com/jptdr/2050-120X/3/1
http://dx.doi.org/10.7243/2050-120X-3-1
[9] Huang, Y.Q., Tan, Z.Y., Luo, L., Yang, H., Tong, C.M., Chen, W.F., Huang, T.Y. and Liu, R.L. (2014) The Polymorphism and Transformation of (3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyi-soindoline-1,3-dione (SU2162)—A Novel Anticancer Compound. Journal of Crystallization Process and Technology, 4, 27-30.
http://dx.doi.org/10.4236/jcpt.2014.41004
[10] Sinko, P.J. (2006) Martin’s Physical Pharmacy and Pharmaceutical Sciences. 5th Edition, Lippincott Williams & Wilkins, Philadelphia.
[11] Brittain, H.G. (1995) Physical Characterization of Pharmaceutical Solid. Vol. 70, Marcel Dekker, New York.
http://dx.doi.org/10.1201/b14204